ProCE Banner Activity

A Comprehensive Look at Tardive Dyskinesia Management

Podcast Episodes
In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.

Released: October 28, 2022

Expiration: October 27, 2023

Share

Faculty

Robert O. Cotes

Robert O. Cotes, MD

Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Teva

Faculty Disclosure

Primary Author

Robert O. Cotes, MD

Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Robert O. Cotes, MD: researcher: Alkermes, Lundbeck, Otsuka, Roche; independent contractor: Saladax.

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Jonathan M. Meyer, MD: consultant/advisor/speaker: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America, Sunovion, Teva.